- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01473823
Treatment of IgE Associated Eczema With Omega-3 Long Chain Polyunsaturated Fatty Acids in Infancy and the Development of Bronchial Asthma in Childhood (Omega-Treat)
Although some causal factors in allergy development such as allergen exposure and environmental pollution have decreased during recent years, the incidence of the allergic diseases has increased in the Western world. Since the genetic predisposition to develop allergies cannot change in such a short time it is conceivable that, instead of the emerging of some new and unknown risk factors, some protective factors seem to have disappeared in the Western world.
Allergic disease is a tendency to develop allergies to allergens in the surrounding environment. The most common symptoms are eczema and food allergy in the early life, bronchial asthma (AB) later in childhood and allergic rhino conjunctivitis (ARC) during school age and adolescence, the so-called allergic march. Some person may develop only one, but others some or all of the symptoms. Inheritance, environment and allergen exposure are important factors affecting this march but there are important factors that predict later development of diseases. Sensitization to egg (positive skin prick test or specific IgE to egg in the serum) combined with skin problems in infancy predispose strongly to the development of allergic asthma in later life.
The purpose of this work is to supply children with early development of IgE associated eczema and food allergy with omega-3 LCPUFA before the age of 12 months and assess the effect of the supplementation on the future development of skin symptoms, food allergy, sensitisation against inhalant allergens and asthma in these children. We will also assess immunological markers of Th2-skewed immunity in relation to clinical effect of the supplementation.
Families with children younger than 12 months referred to the paediatric department at Linköping University Hospital, Motala, Norrköping and Jönköping Hospitals in the South East of Sweden, with the diagnosis IgE associated eczema and sensitised against food allergens (egg, milk, wheat and/or soya) will be invited to participate in this study. Clinical examination by a paediatrician and assessment of disease severity with SCORAD will be performed by a research nurse at inclusion. The children will be assessed every six months by a nurse until 2.5 years of age and by a paediatrician at 3 years of age. Later clinical assessment will be performed yearly until age 7.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Linköping, Sweden
- Allergicentrum
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Eczema and sensitisation to food allergens
Exclusion Criteria:
- Fish allergy within family
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo oil
Canola oil with high oleic acid content flavored with lemon supplied as 5 ml daily.
|
Dosage is 5 ml daily until age 3 years.
|
Active Comparator: Omega-3 LCPUFA
The omega-3 LCPUFA supplementation comprises of 5 ml daily of "Möller's Tran" flavored with lemon.
This dose provides the child with 1200 mg of omega-3 fatty acid of which 600 mg is DHA and 400 mg is EPA.
|
Dosage is 5 ml daily until age 3 years.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Prevalence of bronchial asthma
Time Frame: 7 years
|
7 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Severity of allergic symptoms and sensitisations to inhalants
Time Frame: 3 years
|
3 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Karel Duchén, MD, PhD, Ostergotland CC
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OT-013
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eczema
-
Technical University of MunichCelgene CorporationCompletedEczema | Nummular Eczema | Dermatitis Eczema | Nummular DermatitisGermany
-
Odense University HospitalCompletedVesicular Palmoplantar Eczema | PompholyxDenmark
-
Gary GoldenbergCompletedHand Eczema | Foot EczemaUnited States
-
University Hospitals Coventry and Warwickshire...University of WarwickNot yet recruitingCancer | Skin Cancer | Dry Skin; Eczema | Medical Device Site EczemaUnited Kingdom
-
Zealand University HospitalUniversity of Copenhagen; Danish Working Environment FundCompleted
-
SalvatCompleted
-
University Hospital Bispebjerg and FrederiksbergStatens Serum InstitutRecruiting
-
BayerCompleted
-
Cosmetique Active InternationalCompleted
Clinical Trials on Omega-3 LCPUFA
-
Swiss Federal Institute of TechnologyNorth-West University, South AfricaCompleted
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedBreast Neoplasms | ArthralgiaUnited States
-
Materna LaboratoriesCompleted
-
Pennington Biomedical Research CenterCompleted
-
AstraZenecaCompletedDiabetes Mellitus, Type 2 | Exocrine Pancreatic InsufficiencySweden, Poland, Latvia, Denmark, Hungary, Slovakia
-
Appalachian State UniversityCompleted
-
Seoul National University HospitalUnknown
-
Université de SherbrookeNot yet recruiting
-
Collegium Medicum w BydgoszczyUnknownChronic Kidney Disease | Cardiovascular ComplicationsPoland
-
Haukeland University HospitalUniversity of Oslo; University of BergenCompletedCardiovascular Disease